Table 3 Distribution of characteristics in patients with favorable survival prognoses
8 Gy × 1 N patients (%) | 4 Gy × 5 N patients (%) | |
|---|---|---|
Age | ||
≤65 years (N = 120) | 60 (52) | 60 (52) |
≥66 years (N = 112) | 56 (48) | 56 (48) |
Gender | ||
Female (N = 118) | 59 (51) | 59 (51) |
Male (N = 114) | 57 (49) | 57 (49) |
ECOG Performance status | ||
1–2 (N = 192) | 96 (83) | 96 (83) |
3–4 (N = 40) | 20 (17) | 20 (17) |
Type of primary tumor | ||
Breast cancer (N = 90) | 45 (39) | 45 (39) |
Prostate cancer (N = 86) | 43 (37) | 43 (37) |
Myeloma/lymphoma (N = 28) | 14 (12) | 14 (12) |
Lung cancer (N = 12) | 6 (5) | 6 (5) |
Unknown primary (N = 2) | 1 (1) | 1 (1) |
Other tumors (N = 14) | 7 (6) | 7 (6) |
Involved vertebrae (n) | ||
1–2 (N = 104) | 52 (45) | 52 (45) |
≥3 (N = 128) | 64 (55) | 64 (55) |
Other bone metastases | ||
No (N = 124) | 62 (53) | 62 (53) |
Yes (N = 108) | 54 (47) | 54 (47) |
Visceral metastases | ||
No (N = 212) | 106 (91) | 106 (91) |
Yes (N = 20) | 10 (9) | 10 (9) |
Interval from tumor diagnosis to MESCC | ||
≤ 15 months (N = 58) | 29 (25) | 29 (25) |
> 15 months (N = 174) | 87 (75) | 87 (75) |
Pre-RT ambulatory status | ||
Not ambulatory (N = 28) | 14 (12) | 14 (12) |
Ambulatory (N = 204) | 102 (88) | 102 (88) |
Time developing motor deficits | ||
1–7 days (N = 12) | 6 (5) | 6 (5) |
8–14 days (N = 40) | 20 (17) | 20 (17) |
> 14 days (N = 180) | 90 (78) | 90 (78) |